Empagliflozin in Pulmonary Arterial Hypertension

Sponsor
Amsterdam UMC, location VUmc
Study ID
NCT05493371
Phase
PHASE2
Status
Completed

Conditions

  • Idiopathic Pulmonary Arterial Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial hypertension.

Key Dates

Start date
Mar 1, 2023
Status verified
Nov 2024
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin

Primary Outcome Measure

Tolerability: the number of patients who have to prematurely discontinue treatment due to intolerability or adverse events. [ Time Frame: 12 weeks ]

Related Studies